HCC
Conditions
Interventions
Experimental group:PD-1 combined with CTLA-4 immunotherapy
Control group:Patients with primary liver cancer treated with other therapeutic approaches (including surgery, ablation, TACE, targeted therapy, and monotherapy immunotherapy)
Sponsors
Chuzhou First People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) All patients must have a pathologically confirmed diagnosis of primary hepatocellular carcinoma; (2) Patients with Child-Pugh A or B liver function and an Eastern Cooperative Oncology Group performance status score of 0–1; (3) No prior immunotherapy for hepatocellular carcinoma prior to study enrollment; (4) Estimated survival of 6 months or longer.
Exclusion criteria
Exclusion criteria: (1) Patients with hepatocellular carcinoma who have previously received tumor-related immunotherapy; (2) Patients with hepatocellular carcinoma classified as Child-Pugh C for liver function and Eastern Cooperative Oncology Group performance status 2; (3) Patients with hepatocellular carcinoma induced by immune system disorders; (4) Patients who have taken hormonal medications within one month prior to study enrollment; (5) Patients who refuse to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective relief rate, ORR;Safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival, PFS;Disease control rate, DCR;Duration of relief, DOR;Overall Survival, OS; | — |
Countries
China
Contacts
Public ContactMeng Zhang
Chuzhou First People's Hospital
Outcome results
None listed